SAM001
Amyotrophic Lateral Sclerosis (ALS)
Pre-clinicalActive
Key Facts
Indication
Amyotrophic Lateral Sclerosis (ALS)
Phase
Pre-clinical
Status
Active
Company
About Samsara Therapeutics
Samsara Therapeutics is a private, pre-clinical biotech pioneering a novel approach to treating neurodegenerative diseases through pharmacological activation of autophagy. The company has built a phenotypic screening platform using patient-derived iPSCs to discover and optimize small molecule autophagy activators, with a pipeline targeting ALS, Parkinson's, and CMT1A. Backed by a $25M Series A led by Apollo Health Ventures and endorsements from major patient advocacy foundations, Samsara is advancing multiple programs toward IND-enabling studies.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis (ALS) Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT520-34 | Neuropore Therapies | Pre-clinical/Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Phase 2/3 (Platform Trial) |
| CNM-Au8 | Clene | Phase 2/3 |
| Masitinib | AB Science | Phase 3 |
| Undisclosed Program | Zhimeng Biopharma | Clinical |
| SLS-005 | Seelos Therapeutics | Platform Trial |
| PMN442 | ProMIS Neurosciences | Preclinical |
| nAV-101 | nVector | Pre-clinical |
| ALTA-808 | Alteron Therapeutics | Preclinical |
| GM6 | Genervon Biopharmaceuticals | Phase 2 |
| Lou Gehrig’s disease | Genclis | Discovery |
| Treg-directed therapy for ALS | Iltoo Pharma | Pre-clinical |